Overview

Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

Status:
RECRUITING
Trial end date:
2030-03-31
Target enrollment:
Participant gender:
Summary
This study is a prospective, multicenter, open-label umbrella clinical study planned to enroll 126 subjects with acute myeloid leukemia/myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. Subjects eligible for enrollment were grouped based on the results of the initial myeloid genomic second-generation sequencing, and were given different regimens of maintenance therapy, with the aim of evaluating the efficacy and safety of the maintenance regimen.
Phase:
PHASE2
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
Decitabine
Sorafenib